Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Fennec Pharmaceuticals Inc

Healthcare CA FRX

12.72CAD
-1.04(7.56%)

Last update at 2026-06-03T15:42:00Z

Day Range

12.7213.21
LowHigh

52 Week Range

7.0813.83
LowHigh

Fundamentals

  • Previous Close 13.76
  • Market Cap310.28M
  • Volume7
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-6.17933M
  • Revenue TTM44.64M
  • Revenue Per Share TTM1.56
  • Gross Profit TTM 40.88M
  • Diluted EPS TTM-0.47

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -10.27477M -0.07100M -16.04500M -23.71400M -17.34600M
Minority interest - - - - -
Net income -10.27477M -0.43600M -16.04500M -23.86100M -17.36500M
Selling general administrative 46.91M 23.05M 20.59M 17.72M 12.24M
Selling and marketing expenses - 18.43M 12.12M 2.79M -
Gross profit 41.59M 44.35M 19.99M 1.45M -
Reconciled depreciation 0.10M 0.80M 0.29M - 0.02M
Ebit - 4.00M -12.93800M -22.58900M -17.22300M
Ebitda -6.86206M 4.80M -12.65100M -22.54300M -17.18500M
Depreciation and amortization - 0.80M 0.29M 0.05M 0.04M
Non operating income net other - - - - -
Operating income -6.86206M 2.57M -12.77100M -22.58900M -17.22300M
Other operating expenses 52.29M 44.97M 34.02M 24.12M 17.22M
Interest expense 2.18M 4.07M 3.39M 0.98M 0.13M
Tax provision 0.11M 0.36M 0.00000M - -
Interest income 0.79M 2.64M 0.44M 0.20M 0.12M
Net interest income -1.29300M -2.47600M -2.95300M -0.93200M -0.07200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.36M 3.39M 0.15M 0.02M
Total revenue 45.42M 47.54M 21.25M 1.53M 0.00000M
Total operating expenses 48.46M 41.79M 32.76M 24.04M 17.22M
Cost of revenue 3.83M 3.18M 1.26M 0.09M -
Total other income expense net -3.41271M -2.63900M -3.27400M -1.12500M -0.12300M
Discontinued operations - - - - -
Net income from continuing ops -9.74100M -0.43600M -16.04500M -23.71400M -17.34600M
Net income applicable to common shares - -0.43600M -16.04500M -23.71400M -17.34600M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 70.07M 44.95M 26.86M 26.94M 22.41M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 5.10M 0.47M 0.04M 0.06M 0.25M
Total liab 35.02M 50.82M 38.49M 29.51M 6.64M
Total stockholder equity 35.05M -5.87200M -11.62200M -2.56900M 15.77M
Deferred long term liab - - - 0.21M 0.03M
Other current liab 5.62M - 3.75M 2.22M 0.88M
Common stock 189.56M - 144.31M 142.59M 140.80M
Capital stock 189.91M 145.61M 144.31M 142.59M 140.80M
Retained earnings -229.36084M -219.68100M -219.24500M -203.20000M -179.48600M
Other liab - - - 0.26M 4.99M
Good will - - - - -
Other assets - - - 0.21M 0.03M
Cash 36.72M 26.63M 13.27M 23.77M 21.10M
Cash and equivalents - - - 23.77M 21.10M
Total current liabilities 10.50M 6.92M 7.55M 4.61M 1.65M
Current deferred revenue 0.25M - - - -
Net debt -36.72105M - 17.68M 1.12M -16.11200M
Short term debt - - 0.02M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - 30.95M 24.90M 4.99M
Other stockholder equity 73.61M - 62.07M 56.80M 53.21M
Property plant equipment - - - - -
Total current assets 66.56M 44.12M 26.86M 26.73M 22.39M
Long term investments - - - - -
Net tangible assets - - - -2.56900M 15.77M
Short term investments - - - - -
Net receivables 23.18M 12.88M 8.81M 1.54M -
Long term debt - 19.34M 30.93M 24.90M 5.00M
Inventory 1.56M 1.06M 2.16M 0.58M -
Accounts payable 4.63M 3.24M 3.78M 2.39M 0.78M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.24M - 1.24M 1.24M 1.24M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.50M 0.82M 0.00600M - 0.03M
Deferred long term asset charges - - - - -
Non current assets total 3.50M 0.82M 0.00600M 0.21M 0.03M
Capital lease obligations 0.00000M 0.00200M 0.02M - -
Long term debt total - - - 25.00M 5.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - - - -
Change to liabilities - - - 1.61M -0.79400M
Total cashflows from investing activities - - - - -
Net borrowings -19.47700M -13.00000M 5.00M 20.17M 4.99M
Total cash from financing activities 25.01M -13.61500M 6.64M 20.73M 4.98M
Change to operating activities - - - 1.61M -0.13800M
Net income -9.91152M -0.43600M -16.04500M -23.71400M -17.34600M
Change in cash 8.83M 13.37M -10.50500M 2.67M -9.24400M
Begin period cash flow 27.89M 13.27M 23.77M 21.10M 30.34M
End period cash flow 36.72M 26.63M 13.27M 23.77M 21.10M
Total cash from operating activities -14.67345M 26.98M -17.14300M -18.05800M -14.22200M
Issuance of capital stock 42.05M - - - 0.00000M
Depreciation 0.10M 0.80M 0.00000M - 0.02M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -1.30037M 0.58M -1.58000M -0.57600M -0.57600M
Change to account receivables -12.65777M -7.87300M -7.26900M -1.54500M -1.54500M
Sale purchase of stock - -0.17600M -0.07800M 0.93M 0.03M
Other cashflows from financing activities -0.19027M -0.43900M 1.64M 25.73M 4.98M
Change to netincome - - - 4.40M 4.04M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -15.09266M 16.94M -6.77800M 1.10M -0.93200M
Stock based compensation 7.03M 5.06M 5.35M 4.09M 3.75M
Other non cash items 10.33M 4.61M 0.33M 0.47M 0.31M
Free cash flow -14.67345M 26.98M -17.14300M -18.05800M -14.22200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
FRX
Fennec Pharmaceuticals Inc		 -1.04 7.56% 12.72 - 21.01 6.95 6.35 4.25 20.27
EPRX
Eupraxia Pharmaceuticals Inc		 - -% 8.87 - - - 8.45 -3.8823
MSCL
Satellos Bioscience Inc.		 -0.01 0.12% 8.30 - - - 5.85 6.47
HBP
Helix BioPharma Corp.		 - -% 1.58 - 3.87 4263.36 9.74 4422.35 -6.3589
SVA
Sernova Corp		 -0.005 3.12% 0.15 - - 65.86 24.15 36.69 -11.2729

Reports Covered

Stock Research & News

View All

Profile

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc

68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709

Key Executives

Name Title Year Born
Mr. Rostislav Raykov CEO & Director 1976
Mr. Robert C. Andrade Chief Financial Officer 1975
Mr. Mark Meier Sr. VP of Commercial NA
Mr. Mark Gowland Controller NA
Mr. Lei Fang Pres of Pharstat Inc NA
Ms. Anne McKay Regulatory Consultant 1954
Mr. Alexander D. Smith M.S. Consultant NA
Mr. Terry Evans Chief Commercial Officer NA
Dr. Pierre S. Sayad M.S., Ph.D. Chief Medical Officer NA
Ms. Christiana Cioffi M.B.A. Chief Strategy Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.